Maa: Kanada
Kieli: englanti
Lähde: Health Canada
DESFLURANE
BLUE-ZONE TECHNOLOGIES LTD
N01AB07
DESFLURANE
100%
LIQUID
DESFLURANE 100%
INHALATION
100
Prescription
INHALATION ANESTHETICS
Active ingredient group (AIG) number: 0128744001; AHFS:
APPROVED
2020-04-17
_ _ _DESFLURANE (desflurane, USP)_ _ _ _ _ _ _ _ _ _ _ _ _ _Page _ 1 _ of _ 47 _ _ PRODUCT MONOGRAPH PR DESFLURANE (desflurane, USP) 100% v/v Liquid for Inhalation Inhalation Anesthetic Blue-Zone Technologies Ltd. Concord, ON Canada L4K 3C1 Date of Preparation: April 16, 2020 SUBMISSION CONTROL NO: 199804 _ _ _DESFLURANE (desflurane, USP)_ _ _ _ _ _ _ _ _ _ _ _ _ _Page _ 2 _ of _ 47 _ _ TABLE OF CONTENTS PRODUCT MONOGRAPH .........................................................................................................1 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION .......................................................................................................... 3 INDICATIONS AND CLINICAL USE................................................................................................................. 3 CONTRAINDICATIONS ...................................................................................................................................... 4 WARNINGS AND PRECAUTIONS ..................................................................................................................... 4 ADVERSE REACTIONS ..................................................................................................................................... 11 DRUG INTERACTIONS ..................................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................................. 18 OVERDOSAGE .................................................................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ....................................................... Lue koko asiakirja